HCPLive Cardiology Podcasts

HCPLive Cardiology

HCPLive Cardiology Podcasts is the home of your favorite expert-led programming in cardiometabolic health, including Don't Miss a Beat and Moving the Needle in Medicine.  Don’t Miss a Beat is hosted by Steve Greene, MD, and Muthiah Vaduganathan, MD, MPH, examining recent advances in clinical care and research in heart failure and cardio-kidney-metabolic health with perspectives from global experts in the field. Moving the Needle in Medicine explores the backstories and nuanced career paths that led the field’s movers and shakers to where they are today. Hosted by Alex Hajduczok, MD, the show will offer listeners insight into the biggest names in cardiology and beyond. Video versions of all shows are available on HCPLive.com.

  1. Moving the Needle in Medicine:Heart Failure, Human Connection, and Career Fulfillment, With Anu Lala, MD

    24. Juni

    Moving the Needle in Medicine:Heart Failure, Human Connection, and Career Fulfillment, With Anu Lala, MD

    The advanced heart failure and transplant workforce faces a measurable recruitment deficit, driven less by competition from critical care subspecialties than by how and when trainees encounter the field during their formation. In this episode of Moving the Needle in Medicine, host Dr. Alex Hajduczok, MD, a cardiologist and heart failure specialist at Oklahoma Heart Institute, sits down with Dr. Anu Lala, director of the Heart Failure Clinical Trials program and program director of the ACGME Fellowship in Advanced Heart Failure and Transplant at Mount Sinai Hospital, as well as a professor of medicine, cardiology, and population health science policy at the Mount Sinai Health System, to explore the personal experiences, mentors, and defining decisions that shaped her career in cardiovascular medicine. Lala reflects on her upbringing in a close-knit Indian American family, emphasizing the influence of family, spirituality, and human connection on both her personal development and professional philosophy. She recounts a pivotal childhood experience caring for her grandmother during an acute myocardial infarction under the guidance of her father, a cardiologist, describing how that moment sparked her fascination with cardiovascular medicine and left a lasting impression on her understanding of service, healing, and patient care. Lala then traces her educational and training journey through Johns Hopkins University, Rutgers Medical School, Mount Sinai, NYU, and Brigham and Women’s Hospital, highlighting the mentors and experiences that reinforced her commitment to advanced heart failure and transplantation. She discusses the unique aspects of the specialty that continue to inspire her, including the opportunity to care for patients during some of the most vulnerable periods of their lives. Beyond the field’s technical complexities, including hemodynamics, mechanical circulatory support, transplantation, and rapidly evolving therapeutics, Lala emphasizes that heart failure medicine is fundamentally about understanding patients’ motivations, values, and purpose. She also reflects on the profound impact of her first transplant procurement and implantation experience, describing transplantation as a powerful reminder of the shared humanity that transcends race, culture, and personal background. The discussion turns to workforce development and the ongoing challenge of recruiting trainees into advanced heart failure. Lala argues that many learners are exposed primarily to the specialty’s most demanding inpatient settings, where physicians are caring for critically ill patients under significant stress. She suggests that this narrow exposure often fails to capture the longitudinal successes that define much of heart failure practice, including patients thriving after transplantation or ventricular assist device implantation. Both speakers emphasize the need for broader trainee experiences that highlight outpatient care, procedural opportunities, long-term patient relationships, and the rewarding outcomes made possible by modern heart failure therapies. They also discuss structural challenges facing the field, including reimbursement disparities and the increasing complexity of multidisciplinary care. The conversation further explores Lala’s transition from fellowship to faculty leadership, including the challenges of navigating early career decisions, balancing personal and professional responsibilities, and identifying the right institutional fit. She shares lessons learned from her move to Mount Sinai, where she built a growing heart failure and transplant clinical trials program, expanded research infrastructure, and developed a strong commitment to mentorship and education. Lala highlights the importance of leadership development, institutional support, and self-reflection, encouraging early-career physicians to remain flexible and recognize that career paths often evolve over time. The episode concludes with a discussion of Lala’s leadership within the heart failure community, including her role with the Journal of Cardiac Failure. She describes the journal’s evolution into a platform focused not only on scientific excellence but also on mentorship, collaboration, and community building. Throughout the conversation, Lala underscores the importance of authenticity, shared leadership, lifelong mentorship, and meaningful relationships, encouraging listeners to define success not by titles or achievements alone, but by their ability to positively influence patients, colleagues, and the future of the field. Editors’ Note: Hajduczok reports disclosures with Impulse Dynamics, Edwards Lifesciences, and Corstasis. Lala reports disclosures with Abiomed, AstraZeneca, Merck & Co., Novo Nordisk, Sequana, Bayer, and others.

    1 Std. 5 Min.
  2. Don't Miss a Beat: Finerenone, FIND-CKD, and the Evolution of CKM, with Katherine Tuttle, MD

    22. Juni

    Don't Miss a Beat: Finerenone, FIND-CKD, and the Evolution of CKM, with Katherine Tuttle, MD

    Check out the video version of this episode on HCPLive!Finerenone's expansion into non-diabetic kidney disease is prompting a broader rethink of how chronic kidney disease is measured, mechanistically understood, and treated across its many causes. On an episode of Don't Miss a Beat recorded at the 10th Annual Heart in Diabetes Meeting, hosts Stephen Greene, MD, meeting co-chair and heart failure specialist at Duke University School of Medicine, and Muthiah Vaduganathan, MD, MPH, codirector of the Center for Cardiometabolic Implementation and cardiologist at Brigham and Women's Hospital, spoke with Katherine Tuttle, MD, professor of medicine at the University of Washington, about the phase 3 FIND-CKD trial and how it informs on the overall role of finerenone (Kerendia) in management of cardiovascular-kidney-metabolic syndrome. FIND-CKD showed finerenone slowed total estimated glomerular filtration rate (eGFR) slope by 0.7 mL/min/1.73 m² per year versus placebo, irrespective of diagnosis. Much of the discussion focused less on the number and more on why it counts as clinically meaningful. Drawing on CKD Prognosis Consortium data from hundreds of thousands of patients, Tuttle explained why eGFR slope reliably predicts kidney failure when a trial runs at least 2 years. CKD progresses rather than striking as a discrete event, so the field has moved toward endpoints measurable without waiting for organ failure or death. On safety, hyperkalemia occurred more often with finerenone than placebo, about 12% versus 3%, though fewer than 1% of patients discontinued. The framing was practical, with background SGLT2 inhibition expected to lower the risk. Mechanism anchors much of the conversation between Tuttle, Greene, and Vaduganathan. Tuttle highlighted how glomerular diseases, like IgA nephropathy, are immunologic disorders needing disease-specific therapy, yet all CKD converges on shared final common pathways of inflammation and fibrosis. Broad agents like finerenone target those pathways, making combination therapy the emerging model, pairing treatment of the inciting disease with control of progression. The group also discussed the field’s trend toward precision nephrology. Protocol biopsies from the Kidney Precision Medicine Project showed only about half of patients labeled as diabetic CKD had classic diabetic nephropathy. A parallel to oncology followed, where deep phenotyping replaced uniform regimens, suggesting not every patient will need every drug. Tuttle positioned finerenone alongside renin-angiotensin system inhibitors and SGLT2 inhibitors as an emerging pillar for non-diabetic CKD, with GLP-1 receptor agonists and endothelin antagonists possibly to come. A pooled analysis of FIDELIO-DKD, FIGARO-DKD, and FIND-CKD showed roughly 30% reductions in kidney and cardiovascular outcomes and an 11% drop in all-cause mortality. The closing point held the cardiorenal patient often arrives through either specialty's door, making preservation of organ function and quality of life the shared aim. Relevant disclosures for Tuttle include Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Novo Nordisk, Roche, and Travere Therapeutics. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.References: Heerspink HJL, Neuen BL, Agarwal R, et al. Finerenone in Persons with Chronic Kidney Disease without Diabetes. N Engl J Med. Published online June 4, 2026. doi:10.1056/NEJMoa2604625 Bayer. Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026. Bayer.com. Published June 2, 2026. Accessed June 21, 2026. https://www.bayer.com/en/us/news-stories/kerendia-in-non-diabetic-chronic-kidney-disease

    22 Min.
  3. Moving the Needle in Medicine: Mentorship, Medicine, and the Making of an Innovator, With Jim Januzzi, MD

    3. Juni

    Moving the Needle in Medicine: Mentorship, Medicine, and the Making of an Innovator, With Jim Januzzi, MD

    The shift from purely clinical heart failure diagnosis to biomarker-guided management unfolded over decades of incremental evidence, institutional skepticism, and a handful of pivotal decisions by a small number of physician-scientists willing to champion tools before their adoption became mainstream. In this episode of Moving the Needle in Medicine, host Alexander Hajduczok, MD, a cardiologist and heart failure specialist at Oklahoma Heart Institute, interviews Jim Januzzi, MD, the Adolph Hutter Professor of Medicine at Harvard Medical School, chief scientific officer and Gibson chair at the Baim Institute for Clinical Research, and a cardiologist at Massachusetts General Hospital, to explore the formative experiences, clinical innovations, and leadership principles that shaped his career and, more broadly, the evolution of modern cardiology. Januzzi described nearly declining the opportunity to conduct the first US-based clinical studies with NT-proBNP in 2002, having positioned himself primarily as a troponin and acute coronary syndrome researcher. The foundational diagnostic and prognostic work he ultimately led at MGH established the NT-proBNP cutoffs now used internationally, and the test has since evolved from an emergency department dyspnea-evaluation tool into a biomarker applied across all phases of heart failure management. He noted sacubitril/valsartan as a particularly meaningful convergence of therapeutic and biomarker science, consistently producing substantial reductions in NT-proBNP regardless of baseline value, a finding he has incorporated as a practical signal for adequacy of neurohormonal blockade. On the broader arc of guideline-directed medical therapy (GDMT), Januzzi reflected on witnessing the introduction of beta-blockers for heart failure as a fellow, a shift once considered counterintuitive, and tracing the subsequent addition of each pillar as a reminder that even well-established treatment paradigms remain open to displacement by rigorous evidence. He described his involvement in the endpoint committee for the EMPA-REG OUTCOME trial as the entry point for his work with SGLT2 inhibitors in heart failure, another opportunity initially approached with ambivalence. Despite four-pillar GDMT, he noted residual event rates underscore the continued need for novel therapeutics, and he expressed enthusiasm for gene-editing approaches and RNA-silencing therapies now entering cardiovascular development pipelines. Across the conversation, Januzzi returned to the role of mentorship and deliberate career planning, including maintaining clinical trial involvement from early protocol design rather than joining established programs at the phase three stage, advocating for sponsorship alongside mentorship, and structuring academic evolution in intentional five-year increments. The discussion positions biomarker-guided heart failure care not as a completed project but as a framework still being refined as the disease's diagnostic boundaries and therapeutic options continue to expand.

    1 Std. 17 Min.
  4. Moving the Needle in Medicine: Work, Burnout, and Professional Priorities, With Andrew Sauer, MD

    6. Mai

    Moving the Needle in Medicine: Work, Burnout, and Professional Priorities, With Andrew Sauer, MD

    A physician's career path is rarely linear and the influences shaping it are seldom predictable. Few understand this better than Andrew Sauer, MD. In this episode of Moving the Needle in Medicine, host Alexander Hajduczok, MD, a cardiologist and heart failure specialist at Oklahoma Heart Institute, sits down with Sauer, director of the Haverty Family Cardiometabolic Center and co-director of the Cardiovascular Research & Clinical Scholars Program at Saint Luke’s Health System. The conversation begins with Sauer reflecting on the formative influences that shaped his path from a rural Midwestern upbringing to a career in advanced heart failure, transplant medicine, and clinical research. Sauer emphasizes the role of early-life adversity, including frequent relocation, blue-collar work, and exposure to hardship, in cultivating resilience and adaptability, traits he identifies as foundational to navigating the demands of medical training and leadership. The sudden cardiac death of his grandfather amid perceived gaps in care, a pivotal moment in his youth, served as a defining motivation to pursue medicine and improve outcomes for underserved patients with cardiometabolic disease. Sauer traces his clinical development through key training experiences at the University of Rochester, Massachusetts General Hospital, and Northwestern University, where he ultimately shifted focus from electrophysiology to advanced heart failure and mechanical circulatory support. He highlights a uniquely challenging fellowship period marked by limited institutional resources, which accelerated his clinical independence and prepared him for early leadership roles. This culminated in a high-risk but transformative decision to cofound a heart failure, LVAD, and transplant program in Kansas, emphasizing the importance of strategic risk-taking, team-based trust, and addressing geographic disparities in access to advanced therapies. The discussion then turns to Sauer’s role in pioneering remote hemodynamic monitoring in his region, particularly through early adoption of CardioMEMS technology and leadership in the GUIDE-HF trial. He underscores how identifying “blue ocean” opportunities - areas of unmet need with limited competition - enabled both clinical innovation and academic visibility. This experience catalyzed his transition toward a more research-focused career. Sauer also offers an in-depth perspective on mentorship, advocating for a diversified, goal-aligned network of mentors rather than reliance on a single advisor. He stresses the importance of seeking guidance tailored to specific objectives and being receptive to critical, rather than affirming, feedback. Throughout the conversation, he reinforces a broader philosophy centered on intentional decision-making, habit formation, and aligning daily actions with long-term outcomes. A significant portion of the discussion addresses physician wellness, where Sauer candidly reflects on personal experiences with burnout, depression, and maladaptive coping mechanisms. He critiques systemic barriers to acknowledging mental health struggles within medicine and calls for greater openness, structural reform, and proactive self-care. He emphasizes that wellness requires deliberate practices, such as physical activity, protected time for creativity, and boundary-setting, in addition to the recognition that resilience alone is insufficient in toxic environments. The episode concludes with reflections on work-life integration, legacy, and personal growth. Sauer highlights a shift in priorities toward family and time autonomy, underscoring the irreplaceable role of personal relationships relative to professional achievements. He introduces practical strategies such as “green zone” scheduling to optimize productivity and creativity, while also advocating for self-compassion, vulnerability, and presence. Ultimately, Sauer encourages listeners to pursue bold, purpose-driven careers, grounded in impact and authenticity, while remaining attentive to personal well-being and meaningful connections.

    1 Std.
  5. Moving the Needle in Medicine: Blazing a Trail in Cardiology, with Martha Gulati, MD, MS

    23. März

    Moving the Needle in Medicine: Blazing a Trail in Cardiology, with Martha Gulati, MD, MS

    A physician's career path is rarely linear and the influences shaping it are seldom predictable. In the inaugural episode of Moving the Needle in Medicine, host Alex Hajduczok, MD, a cardiologist and heart failure specialist at Oklahoma Heart Institute, sits down with Martha Gulati, MD, MS, FACC, FAHA, director of the Davis Women's Heart Center at Houston Methodist and one of the most recognized voices in women's cardiovascular health. The conversation spans 5 decades of professional formation, from a childhood in Ontario marked by early loss to a career defined by landmark research, guideline leadership, and an enduring commitment to a population long underserved by cardiology. Gulati traces her interest in medicine to her mother, a physicist who was once steered away from medicine because it was considered a male field, and to the early death of a parent under a physician's missed diagnosis. Her path toward cardiology solidified in medical school at the University of Toronto, where a mentor's invitation into the catheterization laboratory proved decisive. That same thread of mentorship runs throughout the conversation: Gulati credits a series of physicians, including the late Morton Arnsdorf at the University of Chicago and Len Sternberg in Toronto, with not only opening professional doors but shaping how she thinks about sponsorship, advocacy, and the responsibility of those in senior roles to invest in the careers of others. The episode's most substantive clinical territory covers the origins of Gulati's expertise in women's cardiovascular disease. A lecture by Nanette Wenger, MD, delivered when Gulati was a medical student crystallized the field's foundational failure: women had been systematically excluded from the studies informing cardiovascular care. Rather than accepting this as background knowledge, Gulati made it the organizing principle of her career. She pursued epidemiological training at the University of Chicago, earned a master's degree in health sciences, and published foundational work on exercise capacity in women using the Woman's Take Heart dataset, work appearing first in Circulation and subsequently in the New England Journal of Medicine. That body of research established both her scientific identity and a clinical platform she has continued to build across appointments at Ohio State University, Cedars-Sinai Medical Center, and now Houston Methodist. Gulati also discusses her experience leading the 2021 ACC/AHA Chest Pain Guidelines the first such guideline ever developed, as chair of the writing committee, a role she accepted without prior guideline experience. She describes the political complexity inherent in evidence synthesis when imaging specialties have competing stakes, the iterative nature of responding to thousands of reviewer comments, and the personal satisfaction of successfully incorporating guidance on ischemia with non-obstructive coronary arteries (INOCA) into the final document. The conversation closes with a frank exchange on GLP-1 receptor agonists and their implications for preventive cardiology, physician wellness, and the structural barriers keeping high-cost medications from patients who need them most.

    1 Std. 8 Min.
  6. POLY-HF & the Potential of Polypills in HF, With Ambarish Pandey, MD

    14.11.2025

    POLY-HF & the Potential of Polypills in HF, With Ambarish Pandey, MD

    Welcome back to Don't Miss a Beat!In this episode of Don’t Miss a Beat, cohosts Steven Green, MD, and Muthu Vaduganathan, MD, MPH, sit down with Ambarish Pandey, MD, from UT Southwestern, to discuss the landmark POLY-HF trial, presented at the 2025 American Heart Association Scientific Sessions in New Orleans. The discussion centers on the novel concept of a “polypill” approach for patients with heart failure with reduced ejection fraction (HFrEF), aiming to simplify guideline-directed medical therapy (GDMT) and improve adherence while maintaining safety and efficacy.Key Timestamps00:00:00 Introduction00:00:45 Polypills in cardiovascular medicine00:02:32 Structuring the POLY-HF trial00:05:00 Mechanics of POLY-HF00:07:43 The patient population in POLY-HF00:09:47 Dosing other medications in POLY-HF00:11:54 Results of POLY-HF00:14:57 Reaching endpoints in POLY-HF00:18:52 Safety in POLY-HF00:22:09 Upcoming studies00:23:54 Outro

    25 Min.

  7. 28.09.2025

    Debating Oral Diuretic Intensification as an Endpoint in Heart Failure Trials

    At the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025, hosts Muthiah Vaduganathan, MD, MPH, a cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, and Stephen Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, discussed the evolving role of oral diuretic intensification as a potential endpoint in heart failure clinical trials.Historically, endpoints progressed from all-cause mortality to cardiovascular mortality, then to composites that included heart failure hospitalization and urgent outpatient visits. Recent trials have gone further, considering changes in oral loop diuretic therapy as signals of worsening disease.The rationale for including oral diuretic intensification is its frequency, prognostic value, and potential to increase event capture in trials. Data from real-world cohorts and secondary analyses demonstrate that escalation of oral diuretics is associated with increased risks of hospitalization and death, suggesting it is not a benign event. Incorporating these events could enhance trial efficiency by substantially increasing the number of captured endpoints, allowing for smaller and shorter studies while maintaining clinical relevance.However, challenges remain. Definitions vary across studies, raising questions about what constitutes a meaningful intensification—dose doubling, drug class switching, or short-term use of additional diuretics. Distinguishing heart failure–related changes from adjustments for comorbid conditions such as kidney disease or obesity further complicates endpoint validity. Concerns also exist that clinician-driven medication changes may introduce variability or bias unless standardized symptom-based criteria are applied.Despite these complexities, retrospective analyses suggest consistent findings across different statistical approaches, reinforcing the prognostic importance of oral diuretic changes. Broader adoption would require consensus definitions, regulatory acceptance, and frameworks to account for overlapping events, such as escalation followed by IV diuretics or hospitalization. The speakers concluded that oral diuretic intensification represents an important step toward more inclusive and globally applicable trial endpoints that better capture the continuum of worsening heart failure.Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.References: Greene SJ, Butler J. Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics. Circulation. 2023;148(22):1746-1749. doi:10.1161/CIRCULATIONAHA.123.066915 Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 Chapters00:00 - Introduction and Evolution of Heart Failure Endpoints 03:02 - The Case for Oral Diuretic Intensification as an Endpoint07:06 - Challenges in Adoption and Standardization14:45 - Broader Implications and Summary

    18 Min.
  8. Vericiguat in Heart Failure and the VICTOR Trial, With Javed Butler, MD

    30.08.2025

    Vericiguat in Heart Failure and the VICTOR Trial, With Javed Butler, MD

    At the European Society of Cardiology Congress 2025 in Madrid, hosts Steve Greene, MD, and Muthiah Vaduganathan, MD, MPH, sat down with Javed Butler, MD, to review the results of the highly anticipated VICTOR trial, a companion study to the pivotal VICTORIA trial evaluating vericiguat in heart failure with reduced ejection fraction (HFrEF). While VICTORIA focused on patients recently hospitalized or otherwise destabilized, VICTOR deliberately enrolled the opposite population—ambulatory, stable patients, systematically excluding anyone with a recent hospitalization or outpatient IV diuretic use. As Butler noted, this created one of the most stable trial cohorts in HFrEF to date, with nearly 90% of participants free from hospitalization for over a year at baseline.Key Timestamps:00:00 - Introduction00:51 - Explaining the Patient Cohort03:13 - The VICTORIA Trial03:44 - Designing the VICTOR Endpoint06:08 - Event Rates in Design Versus Execution07:54 - VICTOR Results and Interpretation10:34 - Reducing Heart Failure Mortality Without Impacting Hospitalization15:57 - Is Worsening HF So Different from Outpatient HF?17:29 - VICTOR Related to Mortality Reducing Therapies20:15 - Is Vericiguat Not Primarily a Heart Failure Drug?22:31 - Overlapping Pathways

    25 Min.
Alle anzeigen (38)

Info

HCPLive Cardiology Podcasts is the home of your favorite expert-led programming in cardiometabolic health, including Don't Miss a Beat and Moving the Needle in Medicine.  Don’t Miss a Beat is hosted by Steve Greene, MD, and Muthiah Vaduganathan, MD, MPH, examining recent advances in clinical care and research in heart failure and cardio-kidney-metabolic health with perspectives from global experts in the field. Moving the Needle in Medicine explores the backstories and nuanced career paths that led the field’s movers and shakers to where they are today. Hosted by Alex Hajduczok, MD, the show will offer listeners insight into the biggest names in cardiology and beyond. Video versions of all shows are available on HCPLive.com.

Informationen

Das gefällt dir vielleicht auch